Losatan 25mg 5pcs

Hypertension: Losatan® is indicated for the treatment of all grades of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. Hypertensive patients with left ventricular hypertrophy: Losatan® is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. Nephropathy in type-II diabetic patients: Losatan® is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type-II diabetes and a history of hypertension. In this population, Losatan® reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease.

Losartan, the first of a new class of antihypertensives, is a specific and selective antagonist of angiotensin II at the AT1 sites. Angitensin II is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. Losartan and its principal active metabolite block the vasoconstriction and aldosterone secreting effects of angiotensin II to the AT1 receptor found in many tissues. Losartan is now regarded as the first-line therapy option for treating high blood pressue.

Adult hypertensive patients: The usual starting and maintenance dose is 50 mg once daily for most patients. The maximal antihypertensive effect is attained 3-6 weeks after initiation of therapy. Some patients may receive an additional benefit by increasing the dose to 100 mg once daily. In patients who are salt depleted, corrective measures should be taken before starting Losatan® and the initial dose should be reduced to 25 mg. No dosage adjustment is necessary for patients up to 75 years of age. There is limited clinical experience in older patients and a lower starting dose of 25 mg once daily is recommended. No initial dosage adjustment is necessary in patients with mild renal impairment (i.e. creatinine clearance 20-50 ml/min). For patients with moderate to severe renal impairment (i.e. creatinine clearance <20 ml/min) or patients on dialysis, a lower starting dose of 25 mg is recommended. Hypertensive patients >6 years of age: The usual recommended starting dose is 0.7 mg/kg once daily (up to 50 mg total) administered as a tablet. Dosage should be adjusted according to blood pressure response. Losatan® is not recommended in pediatric patients <6 years of age or in pediatric patients with glomerular filtration rate <30 ml/min/1.73 m2.

No drug interactions of clinical significance have been identified. Compounds that have been studies in clinical pharmacokinetic trials include- Hydrochlorothiazide, Digoxin, Warfarin, Cimetidine, Phenobarbital and Ketoconazole.

Pregnancy & patients who are hypersensitive to the active ingredient or any components of the product.

Adverse effects of Losartan have been reported to be usually mild and transient, and include dizziness and dose-related orthostatic hypotension. Hypotension may occur particularly in patients with volume depletion. Impaired renal function and, rarely, rash, angioedema, and raised liver enzyme values may occur. Hyperkalemia and myalgia have been reported. Losartan appears less likely than ACE inhibitors to cause cough. Others include respiratory tract disorders, back pain, gastrointestinal disturbances, fatigue and neutropenia.